Adagio stock soars on hopes antibody treatment can work against Omicron
December 17, 2021, 3:36 am
Adagio Therapeutics’ stock price more than doubled Thursday on the hopes that its experimental monoclonal antibody treatment may actually work against the Omicron variant. Shares in the company rose 123 percent to close at $14.
keywords
Stock ~ The Boston Globe ~ United States
